Savara (NASDAQ:SVRA) Trading Down 3.9%

Savara Inc (NASDAQ:SVRA) shares traded down 3.9% on Wednesday . The stock traded as low as $4.96 and last traded at $4.96. 751,563 shares were traded during mid-day trading, a decline of 9% from the average session volume of 828,314 shares. The stock had previously closed at $5.16.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on SVRA shares. JMP Securities restated a “market outperform” rating and set a $8.00 price objective on shares of Savara in a report on Thursday. Piper Sandler increased their target price on Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Savara has an average rating of “Buy” and a consensus price target of $8.20.

Savara Stock Down 3.4 %

The firm has a fifty day simple moving average of $4.97 and a 200-day simple moving average of $4.39. The company has a market capitalization of $661.74 million, a PE ratio of -14.52 and a beta of 0.77. The company has a debt-to-equity ratio of 0.19, a quick ratio of 15.66 and a current ratio of 15.66.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. Equities research analysts anticipate that Savara Inc will post -0.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Savara

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. increased its stake in Savara by 30.9% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company’s stock valued at $30,008,000 after buying an additional 1,874,000 shares during the period. Jennison Associates LLC boosted its position in Savara by 44.6% during the third quarter. Jennison Associates LLC now owns 3,866,762 shares of the company’s stock valued at $14,616,000 after purchasing an additional 1,192,730 shares during the last quarter. Vivo Capital LLC purchased a new position in Savara in the third quarter valued at about $7,232,000. Polar Capital Holdings Plc acquired a new position in Savara in the 3rd quarter worth about $3,780,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Savara during the 4th quarter worth about $74,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.